Skip to main navigation Skip to search Skip to main content

Prevalence and Incidence of Difficult-to-Treat Asthma in Children Between 2010 and 2020: Promise and Pitfalls of Using Routinely Acquired Prescribing Data

  • Valeria Perugini
  • , Jenni K. Quint
  • , Louise Fleming
  • , Francine M. Ducharme
  • , Theresa W. Guilbert
  • , Alan Kaplan
  • , Desiree Larenas-Linnemann
  • , Clare S. Murray
  • , Nikos G. Papadopoulos
  • , James Paton
  • , Wanda Phipatanakul
  • , David B. Price
  • , Dermot Ryan
  • , Stanley J. Szefler
  • , Stephen Turner
  • Respiratory Effectiveness Group, Cambridge, UK.
  • Imperial College London
  • Royal Brompton and Harefield NHS Foundation Trust
  • University of Montreal
  • University of Cincinnati
  • University of Toronto
  • Fundación Clínica Médica Sur
  • University of Manchester
  • University of Athens
  • University of Glasgow
  • Boston Children's Hospital
  • University of Colorado Anschutz Medical Campus

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Limited whole-population data and heterogeneous definitions complicate efforts to describe the burden of difficult-to-treat asthma (DTTA). Objective: To determine the prevalence of DTTA in a large population of children using three different definitions and assess the incidence of DTTA, prevalence of high short-acting β-agonist (SABA) use, and potential eligibility for biologic therapies. Methods: This was a retrospective cohort study using primary care prescribing data from 3- to 15-year-olds between 2010 and 2020. We defined DTTA using three international guideline-based definitions. High SABA use was defined as more than three canisters annually. Adequate adherence was defined as a controller medication possession rate greater than 80%. We used National Institute for the Health and Care Excellence criteria to estimate eligibility for biologic therapies. Results: Among 2,364,000 children, 127,921 had asthma (mean age 7.2 years; 61% male). The prevalence of DTTA was between 13.1 and 15.7 per 1,000 children, depending on the definition applied, with the highest prevalence in 2010. The annual DTTA incidence among 6-to-15-year-olds varied between 4.7 and 7.6 per 1,000 children with preexisting asthma. High SABA use among 6- to 15-year-olds was observed in 68% of all children with asthma. Before adherence to preventer therapy was considered, 1.6% of all children with asthma were potentially eligible for biologic therapies, but only 4% of these were judged to be adherent. Conclusions: Prescribing data can identify children with potential DTTA and should prompt clinical review, but they may overestimate prevalence. High short-acting β-agonist use and low adherence highlight opportunities for improved asthma management through targeted digital monitoring and data-driven approaches.
Original languageEnglish
Pages (from-to)2595-2603.e4
Number of pages13
JournalThe Journal of Allergy and Clinical Immunology: In Practice
Volume14
Issue number11
Early online date5 Nov 2026
DOIs
Publication statusPublished - Nov 2026

Data Availability Statement

The dataset used for this study was partially funded by Optimum Patient Care Limited, through access to the Optimum Patient Care Research Database (www.opcrd.co.uk). Data access was granted under a limited license from Optimum Patient Care Limited, and the dataset and is not publicly available; and study execution was approved by recognized experts affiliated to the Respiratory Effectiveness Group. However, the interpretation and conclusions contained in this report are those of the authors alone.

Funding

This study was funded by an unrestricted grant from Sanofi Pharmaceutical Inc.

Funders
Sanofi-Aventis

    Keywords

    • Asthma
    • Child
    • Epidemiology

    Fingerprint

    Dive into the research topics of 'Prevalence and Incidence of Difficult-to-Treat Asthma in Children Between 2010 and 2020: Promise and Pitfalls of Using Routinely Acquired Prescribing Data'. Together they form a unique fingerprint.

    Cite this